Nonvalvular Atrial Fibrillation Therapeutics
1. Eliquis patent expiration
Treatment: Reducing the risk of stroke and systemic embolism; Prophylaxis of pulmonary embolism
ELIQUIS's oppositions filed in EPO
ELIQUIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6413980 | BRISTOL MYERS SQUIBB | Nitrogen containing heterobicycles as factor Xa inhibitors |
Dec, 2019
(6 years ago) | |
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(5 years from now) | |
|
US6967208 (Pediatric) | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
May, 2027
(1 year, 4 months from now) | |
|
US9326945 (Pediatric) | BRISTOL MYERS SQUIBB | Apixaban formulations |
Aug, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-681) | Mar 03, 2017 |
| New Indication(I-661) | Aug 21, 2017 |
| New Indication(I-690) | Aug 21, 2017 |
| New Indication(I-691) | Aug 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| New Patient Population(NPP) | Apr 17, 2028 |
| New Strength(NS) | Apr 17, 2028 |
| Pediatric Exclusivity(PED) | Oct 17, 2028 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 April, 2025
Dosage: TABLET; TABLET, FOR SUSPENSION
How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage
ELIQUIS family patents
